Alexion Buys Taligen, Adding A Complement To Its Research Pipeline
This article was originally published in The Pink Sheet Daily
Alexion acquired the privately-held biotech for $111 million plus milestone payments
You may also be interested in...
The pharma pledges $50 million to the California firm’s new seventh round, which it anticipates closing more than eight years after its sixth. For GSK, it’s the latest tie-up with a VC firm as part of a regional investment strategy.
The biotech, which is enjoying growing sales of high-priced, ultra-orphan terminal complement inhibitor Soliris, also has a pipeline of four other clinical and preclinical candidates for rare diseases.
Alexion could pay as much as $1.08 billion for access to Enobia's mid-stage rare disease compound asfotase alpha.